• Species Reactivity

  Human

• Specificity

  Detects human LRRC32/GARP in ELISAs.

• Source

  Monoclonal Rat IgG    _2A Clone # 855151

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Chinese hamster ovary cell line CHO-derived recombinant human LRRC32/GARP    
  Met1-Asn627    
  Accession # Q14392

• Formulation

  Supplied in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 488

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Flow Cytometry

  5 μL/10    ⁶ cells

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Protect from light.    Do not freeze.    

• 12 months from date of receipt, 2 to 8 °C as supplied.

Background: LRRC32/GARP

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature human LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine?rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2, 3). Within the ECD, human LRRC32 shares approximately 80% aa sequence identity with mouse and rat LRRC32. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Human LRRC32 is identified as a lineage specific key receptor for human T cells. It is selectively expressed on activated FOXP3  ⁺ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of na?ve T cells (6-8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress na?ve T cell proliferation (11).

• References:

1. Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.

2. Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.

3. Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.

4. Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.

5. Macaulay, I.C. et al. (2007) Blood 109:3260.

6. Wang, R. et al. (2008) PloS ONE 3:e2705.

7. Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.

8. Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.

9. Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.

10. Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.

11. Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.

• Long Name:

  Leucine-rich Repeat Containing 32/Glycoprotein A Repetitions Predominant

• Entrez Gene IDs:

  2615 (Human); 434215 (Mouse)

• Alternate Names:

  D11S833E; D11S833Eleucine-rich repeat-containing protein 32; GARP; GARPGarpin; Garpin; Glycoprotein A repetitions predominantgarpin; leucine rich repeat containing 32; LRRC32